Quetmolimab: A Deep Dive into KANAb 001 and E-6011 The agent, E-6011, is a new treatment focused on PD-1. Early medical findings from these studies, KANAb 001 and E-6011, demonstrate significant effects in different https://www.targetmol.com/compound/quetmolimab